



Cempra, Inc.
 Investor Relations Department
 6320 Quadrangle Drive Suite 360
 Chapel Hill, NC 27517
 United States

Visit IR website [↗](#)
 Sign-up for email alerts [↗](#)

| | |
|----------------------------------|----------------------------|
| NASDAQ: CEMP ¹ | |
| Last Trade: | 4.30 |
| Trade Time: | 4:00 PM ET Jul 26, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 2.55 - 26.95 |
| Volume | 3 |
| Market Cap. (\$M) | 225.750 |
| Shares Out (M) | 52.500 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in the treatment of infectious diseases, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 20, 2017*
[Cempra to Report Second Quarter 2017 Financial Results](#)
- Jun 2, 2017*
[Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media](#)
- Jun 2, 2017*
[Cempra to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 10, 2017*
[Cempra Presents Data on Ophthalmic Solithromycin at ARVO](#)
- Apr 28, 2017*
[Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 28, 2017*
[Annual Report \(10-K\)](#)
- Apr 6, 2016*
[Definitive Proxy Statement](#)
- Apr 28, 2017*
[Quarterly Report \(10-Q\)](#)
- Oct 27, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 1, 2016*
[Quarterly Report \(10-Q\)](#)